NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-18-882 from the NIH Guide for Grants and Contracts. The goal of the program is to support the development of research capability in mobile and wireless health technology (e.g., wearable devices, mobile applications, electronic health records, data analytics). Special emphasis will be given to independent behavioral and social sciences investigators who seek to train in a STEM discipline (e.g., big data analysis, computational modeling, engineering, computer science, and mathematics) or to STEM scientists who which to train in a behavioral and social science discipline.
Funding Opportunity RFA-HG-18-006 from the NIH Guide for Grants and Contracts. This program aims to support researchers to do highly innovative work on important problems in genomics. The PIs should be creative investigators, early in their careers, who are part of consortia, large research groups, or other team science efforts. They should have shown the potential to make important contributions to the field of genomics. PIs will have some flexibility to pursue their new ideas and take advantage of opportunities that arise during the course of this award.
Notice NOT-FD-18-014 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-633 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-19-151 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for an Early Psychosis Intervention Network (EPINET) National Data Coordinating Center (ENDCC) to support and extend the work of regional scientific hubs described in companion announcement RFA-MH-19-150. The ENDCC will lead efforts to (a) harmonize early psychosis common data elements, standard measures, and uniform data collection procedures across multiple early psychosis Coordinated Specialty Care (CSC) clinics within regional networks; (b) build informatics infrastructure and pipelines necessary to gather and store de-identified, patient-level data collected across all regional clinics; (c) develop data analysis, presentation, and reporting tools to facilitate timely quality improvement and program evaluation efforts across regional networks; (d) identify innovative CSC assessment, intervention, and quality improvement practices for broad dissemination; and (e) and make national CSC data available for practice-based research to improve early identification, diagnosis, clinical assessment, intervention effectiveness, service delivery and health outcomes in early psychosis. The ENDCC will combine regional datasets into a national repository of early psychosis common data elements, clinical measures, assessment and intervention strategies, and de-identified person-level data from patients receiving CSC services. Data assembled by the ENDCC will facilitate large-scale, practice-based research to improve early identification, diagnosis, clinical assessment, intervention effectiveness, and health outcomes in clinics offering evidence-based care to persons in the early stages of psychotic illness.
Funding Opportunity RFA-MH-19-150 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Early Psychosis Intervention Network (EPINET) regional scientific hubs to support practice-based research to improve diagnosis, clinical assessment, intervention effectiveness, service delivery, and health outcomes in clinics offering evidence-based specialty care to persons in the early stages of psychotic illness. Each EPINET regional scientific hub will link multiple early psychosis clinical service programs through (a) standard measures of early psychosis clinical features, services, and treatment outcomes; (b) informatics tools to collect de-identified, person-level data across sites; and (c) a unified approach for aggregating and analyzing pooled data. Large, integrated datasets are expected to facilitate rigorous quality improvement and program evaluation efforts within regional networks. In addition, each regional scientific hub will propose mental health services and intervention research to advance the learning health care goals of measurement-based treatment, continuous improvement and innovation in care delivery, and practice-based research to drive the process of scientific discovery. Regional scientific hubs selected for funding will collaborate closely with the EPINET National Data Coordinating Center, which is described in companion announcement RFA-MH-19-151.
Funding Opportunity PAR-18-880 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.
Notice NOT-FD-18-015 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-19-020 from the NIH Guide for Grants and Contracts. The National Heart, Lung, and Blood Institute invites cooperative agreement (U01) applications to serve as the Research Center (RC) for the Molecular Atlas of Lung Development Program (LungMAP), Phase 2. The overall objective of LungMAP is to better understand human lung development through building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 2 of LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung. Phase 2 of LungMAP will focus on human lung only and will extend the scope to cover normal lung development into early adulthood (up to 25 years old), as well as abnormal lung development in selected neonatal and pediatric rare lung diseases. The purpose of the LungMAP RCs will be to generate the molecular profiling data of the developing human lung. Applicants are not required to have been funded in Phase 1 (RFA-HL-14-008) in order to submit applications for Phase 2.
Funding Opportunity RFA-HL-19-021 from the NIH Guide for Grants and Contracts. The National Heart, Lung, and Blood Institute invites cooperative agreement (U01) applications to serve as the Research Center (RC) for the Molecular Atlas of Lung Development Program (LungMAP), Phase 2. The overall objective of LungMAP is to better understand human lung development through building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 2 of LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung. Phase 2 of LungMAP will focus on human lung only and will extend the scope to cover normal lung development into early adulthood (up to 25 years old), as well as abnormal lung development in selected neonatal and pediatric rare lung diseases. The purpose of the LungMAP RCs will be to generate the molecular profiling data of the developing human lung. Applicants are not required to have been funded in Phase 1 (RFA-HL-14-008) in order to submit applications for Phase 2.
Funding Opportunity RFA-HL-19-022 from the NIH Guide for Grants and Contracts. The National Heart, Lung, and Blood Institute invites cooperative agreement (U24) applications to serve as the Data Coordinating Center (DCC) for the Molecular Atlas of Lung Development Program (LungMAP), Phase 2. The overall objective of LungMAP is to better understand human lung development through building an open-access reference resource of a comprehensive, dynamic, 3-D molecular atlas of the late-stage developing human lung with data and reagents available to the research community. Phase 2 of LungMAP will continue to generate and integrate high-resolution, multiscale molecular profiles associated with spatial information to provide molecular characterizations of functionally and anatomically defined cell types in the developing human lung. Phase 2 of LungMAP will focus on human lung only and will extend the scope to cover normal lung development into early adulthood (up to 25 years old), as well as abnormal lung development in selected neonatal and pediatric rare lung diseases. The DCC will perform data collection, integration, and analysis; develop and maintain the LungMAP database and website; and coordinate research activities of the Human Tissue Core (HTC) and the Research Centers (RCs). Applicants are not required to have been funded in Phase 1 (RFA-HL-14-009) in order to submit applications for Phase 2.
Notice NOT-TR-18-027 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HD-19-008 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support a national program of mentored advanced career development and training in research for junior faculty in pediatric critical care medicine and pediatric trauma surgery. Such a program is necessary to fuel the pipeline of well trained young investigators and advance research in these two clinically demanding fields.
Notice NOT-HS-18-012 from the NIH Guide for Grants and Contracts
Notice NOT-HD-18-015 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-214 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-090 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-213 from the NIH Guide for Grants and Contracts
Expanding Extramural Research Opportunities at the NIH Clinical Center (U01 Clinical Trial Optional)
Funding Opportunity PAR-18-879 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support extramural investigator-initiated clinical research in collaboration and partnership with intramural investigators at the NIH Clinical Center in Bethesda, MD. This new FOA will leverage the resources (inpatient and outpatient) and assets of the NIH Clinical Center (e.g., scientific, clinical trial and expertise, nursing, beds, critical care services, ambulatory care services, laboratories, imaging, biostatistics, protocol development, regulatory guidance, clinical trials management and safety oversight) in accelerating the discovery and translation from lab to clinic of therapies for allergy, asthma, autoimmune disease and transplantation. Extramural scientists proposing research within NIAIDs priorities has the opportunity to utilize this unique resources of the Clinical Center (for a description of resources, see https://clinicalcenter.nih.gov/translational-research-resources/resources.html). This FOA will specifically support hypothesis-driven mechanistic studies alone or within clinical projects employing small Phase 0, 1, and/or 2a clinical trial designs.
Funding Opportunity PAR-18-878 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R01 grant applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease.